Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group

Front-line bevacizumab (BEV) in combination with taxanes offers benefit in progression-free survival (PFS) in metastatic breast cancer (mBC). The medical records of mBC patients, treated with front-line BEV-based chemotherapy, were retrospectively reviewed in order to generate real life safety and e...

Descripción completa

Detalles Bibliográficos
Autores principales: Kokkali, Stefania, Saloustros, Emmanouil, Stefanou, Dimitra, Makrantonakis, Paris, Kentepozidis, Nikolaos, Boukovinas, Ioannis, Xenidis, Nikolaos, Katsaounis, Panagiotis, Ardavanis, Alexandros, Ziras, Nikolaos, Christopoulou, Athina, Rigas, George, Kalbakis, Kostas, Vardakis, Nikolaos, Emmanouilides, Christos, Athanasiadis, Ilias, Anagnostopoulos, Athanassios, Hatzidaki, Dora, Prinarakis, Efthimios, Simopoulou, Foteini, Kotsakis, Athanasios, Georgoulias, Vassilis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871254/
https://www.ncbi.nlm.nih.gov/pubmed/35200604
http://dx.doi.org/10.3390/curroncol29020105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871254/
https://www.ncbi.nlm.nih.gov/pubmed/35200604
http://dx.doi.org/10.3390/curroncol29020105

Ejemplares similares